Almotriptan in the acute treatment of migraine in patients 11–17 years old: an open–label pilot study of efficacy and safety

Charles, James

doi:10.1007/s10194-006-0288-0

Cited by 23 publications

(10 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Findings from 2 recently published studies have suggested that oral almotriptan is effective for the acute treatment of migraine in some adolescents. A pilot study of open‐label almotriptan for the acute treatment of migraine that enrolled 17 patients 11‐17 years of age demonstrated improvements in headache pain intensity and migraine‐associated disability after almotriptan treatment in all but 2 patients; this study also reported good treatment‐related tolerability 10 . Following that study, a randomized, double‐blind, placebo‐controlled multicenter trial that enrolled 866 patients 12‐17 years of age demonstrated significantly greater 2‐hour pain relief rates for patients in the 15‐17 years of age subgroup after treatment with almotriptan 6.25 mg, 12.5 mg, and 25.0 mg compared with placebo.…”

mentioning

confidence: 66%

Long‐Term, Open‐Label Safety Study of Oral Almotriptan 12.5 mg for the Acute Treatment of Migraine in Adolescents

Berenson

Vasconcellos²,

Pakalnis³

et al. 2010

Headache

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 66%

Long‐Term, Open‐Label Safety Study of Oral Almotriptan 12.5 mg for the Acute Treatment of Migraine in Adolescents

Berenson

Vasconcellos²,

Pakalnis³

et al. 2010

Headache

View full text Add to dashboard Cite

show abstract

“…[53] An open-label pilot study investigated the safety and efficacy of almotriptan in the acute treatment of migraine with or without aura in 15 patients (11-17 years of age). [47] Almotriptan was well tolerated in doses ranging from 6.25 mg (bodyweight <50 kg; n = 2) to 12.5 mg (bodyweight >50 kg; n = 13). Thirteen patients reported benefit and continued normal activities, while no efficacy was demonstrated in two patients.…”

Section: Almotriptanmentioning

confidence: 99%

The Use of Triptans for Pediatric Migraines

Eiland

Hunt

2010

Pediatric Drugs

View full text Add to dashboard Cite

Migraine headaches frequently occur in the pediatric population, with a prevalence of 3% in children 2-7 years of age, 4-11% in children 7-11 years of age, and 8-23% in children 11 years of age and older. Migraine without aura is more than twice as common as migraine with aura in children. Headaches are the third leading cause of emergency room referrals and rank in the top five health problems of children. The 2004 American Academy of Neurology's treatment parameter for migraine in children and adolescents recommended that nasal sumatriptan be considered for acute treatment; however, data were lacking to make a decision regarding the available oral triptans at that time. The more recently released European guidelines discuss three different triptans for use in children but no specific triptan was recommended. Currently, six of the seven available triptans have been studied for efficacy and safety in the pediatric population; however, only a few well controlled clinical studies have been conducted. Sumatriptan has the most available data on outcomes in general, with nasal sumatriptan showing the most positive results. Nasal sumatriptan is approved in children older than 12 years of age in Europe. Oral sumatriptan does not show any clinical benefit versus placebo in children. Rizatriptan and zolmitriptan have conflicting efficacy and safety data, with most studies favoring the use of oral rizatriptan and nasal zolmitriptan. Almotriptan is the first triptan to obtain a US FDA indication in adolescents with migraines lasting 4 or more hours. This approval was based upon two studies, one large clinical trial and one very small, open-label, pilot study. At this time, there are insufficient data to recommend naratriptan and eletriptan for first- or second-line use in pediatric patients with migraines. There are currently no efficacy data for frovatriptan in pediatric patients, which limits its use in this population. Adverse effects of triptans and pharmacokinetic data in children and adolescents are similar to those in adults. The triptan class should be considered as an acute treatment option for children and adolescents with migraines, although their use is mostly 'off-label'. Of the available triptans, there are more positive efficacy data for sumatriptan and zolmitriptan nasal sprays, and rizatriptan and almotriptan tablets than for the other triptans.

show abstract

“…52 Diagnosis was based on International Headache Society (IHS) criteria. All patients had normal brain imaging studies and no developmental, behavioural or medical problems.…”

Section: Efficacy and Safetymentioning

confidence: 99%

Almotriptan: Review of Efficacy in Treating Migraine in Adolescents

Gori

Lucchesi²,

Murri³

2011

Clinical Medicine Reviews in Therapeutics

View full text Add to dashboard Cite

Migraine is a common disabling neurological disorder, often starting in children and adolescents. Triptans, a class of selective 5HT1b/d receptor agonists, have been shown to be effective and well-tolerated as acute therapy in adult migraineurs. Data examining efficacy and tolerability of triptans in adolescents are limited compared with adults. Almotriptan has recently been approved by the USA regulatory authorities (FDA) for the acute treatment of migraine headache in adolescent patients (age 12 to 17 years). A double-blind placebo-controlled, parallel group, multicenter trial demonstrated that oral almotriptan in effective and well tolerated in adolescents, with the 12,5 mg dose associated with the most favourable profile. The aim of this review is to give an overview of clinical data about efficacy and safety of oral Almotriptan in adolescents.

show abstract

Almotriptan in the acute treatment of migraine in patients 11–17 years old: an open–label pilot study of efficacy and safety

Cited by 23 publications

References 9 publications

Long‐Term, Open‐Label Safety Study of Oral Almotriptan 12.5 mg for the Acute Treatment of Migraine in Adolescents

Long‐Term, Open‐Label Safety Study of Oral Almotriptan 12.5 mg for the Acute Treatment of Migraine in Adolescents

The Use of Triptans for Pediatric Migraines

Almotriptan: Review of Efficacy in Treating Migraine in Adolescents

Contact Info

Product

Resources

About